Literature DB >> 8676655

Response to dexamethasone in patients with fluid retention after docetaxel.

S Chan, L Winterbottom, S Gardner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8676655     DOI： 10.1016/s0140-6736(96)91723-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.

Authors:  Agustin A Garcia; Syma Iqbal; David Quinn; Susan Edwards; Heinz Josef Lenz; Jeff Weber
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

Review 2.  Docetaxel: an update of its use in advanced breast cancer.

Authors:  D P Figgitt; L R Wiseman
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 3.  Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.

Authors:  R Bruno; N Vivier; C Veyrat-Follet; G Montay; G R Rhodes
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 4.  Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers.

Authors:  F M Muggia
Journal:  Drugs       Date:  1997       Impact factor: 9.546

5.  Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis.

Authors:  Yuko Kanbayashi; Koichi Sakaguchi; Fumiya Hongo; Takeshi Ishikawa; Yusuke Tabuchi; Osamu Ukimura; Koichi Takayama; Tetsuya Taguchi
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.